ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition

ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition

ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On July 17, 2019, Abbott Laboratories announced its results of operations for the second quarter 2019.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the estimated impact of U.S. tax reform, the acquisition of an R&D asset and the cost associated with the early extinguishment of debt, charges related to impairment of certain assets, and tax benefits associated with specified items and share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits

EX-99.1 2 a19-12883_1ex99d1.htm EX-99.1 Exhibit 99.1     News Release   Abbott Reports Second-Quarter 2019 Results   ·                 Accelerated and sustainable growth driven by strong performance across portfolio ·                 Raising full-year guidance for organic sales growth to 7 to 8 percent ·                 Double-digit EPS growth exceeded expectations; raising full-year forecast ·                 Long-term growth drivers — FreeStyle Libre,…
To view the full exhibit click here


Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.